CORE ONE LABS

Core One Labs Inc.
CSE: COOL

OTCQX: CLABF

Frankfurt: LD6, WKN: A14XHT

Core One Labs' Subsidiary, Core Isogenics Inc., Transfers Core Isogenics' Seedlings from Its Nursery Facility to Its Cultivation Facility

Vancouver, British Columbia, Canada, October 10, 2019, Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) ("COOL" or the "Company") announces it has transferred Core Isogenic seedlings from its nursery facility to its cultivation facility.

Core Isogenics Inc. now holds both a yearly renewable Provisional Cultivation License and a yearly renewable Provisional Nursery license, and is positioned to control its plant genetics from seed to harvest. The transfer of seedlings from the nursery into the cultivation facility is the beginning of a year round continuous process of seed to harvest for the Company's cannabis production facility in Adelanto, CA.

The Cultivation facility comprises a vegetative room and a flowering room. The vegetative room houses a two-story state-of-the-art rolling table system and 192 lights. The flower room includes the same two-story state-of-the-art rolling table system, but holds 288 lights. Both the flowering and the vegetative rooms have automated watering systems in order to keep an accurate feeding regimen for the plants and reduce the amount of labor required to service the plants.

As of the date of this news release, Core Isogenics has transferred 2400 clones into the vegetation side of the cultivation facility, approximately 28% of the available vegetation area. The clones were taken from mother plants grown by Core Isogenics from seed. In approximately four weeks, these immature plants will be moved into the flowering area of the cultivation facility to complete the growth cycle. Core Isogenics will repeat this procedure every week to create a constant cultivation and harvest routine. The benefit of a constant weekly harvest is the continuous production of bio-mass without interruption.

The genetics for all seedlings and clones are produced by Core Isogenics' Nursery located in the same facility. The product grown will be used for the production of CannaStrips™, flower, wholesaled in bulk or broken down into smaller sizes and sold under an in-house brand for the Company's affiliated Highway 395 Dispensary.

About CannaStrips™

CannaStrips™ is a formulated oral strip for effective buccal mucosal delivery that disrupts the barrier created by saliva coating the mucosal membrane for the active materials (in this case cannabinoids) which have been nanoparticulated and encapsulated to penetrate the multiple layers of mucosal and sub-mucosal membranes to the blood stream. Once in the blood stream the encapsulation is undetectable as a foreign material by the liver. This undetectability allows the material to avoid being filtered out of the blood stream by the

liver. The encapsulation also is more effective in penetrating the blood-brain barrier and allowing for greater bioavailability and extending the effective time from a single dose.

About Core Isogenics Inc.

Core Isogenics Inc. is located in Adelanto, California and is a City permitted and State Licensed cultivation and nursery operation in the California cannabis industry. Developing isogenic seed strains and automated cultivation methods for the cannabis industry with Core One Labs Inc. a British Columbia company.

About Core One Labs Inc.

Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities. The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.

Core One Labs Inc. Brad Eckenweiler CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT: InvestorRelations@coreonelabs.ca

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking

statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.